A new treatment for prostate cancer, which is administered orally, would allow patients to recover their quality of life and reduce the risk of death by up to 35% due to this disease. Miguel Álvarez, from the National Institute of Cancerology.
In our country, more than 5 thousand men a year are diagnosed and receive treatment for prostate cancer, of which 25% die in the first year after detecting the disease, according to the Institute, so their timely detection is vital, as explains in the following video of CadenaTres News :
In this sense, the investigation Abiraterone and Increased Survival in Metastatic Prostate Cancer, reveals that patients with advanced metastatic prostate cancer, resistant to castration after chemotherapy, improve their overall survival 3.9 months more when they receive treatment with abiraterone acetate .
In this study, published in The New England Journal of Medicine, it is shown that despite the advanced age and the delicate state of the patients, this treatment is ideal because it is less toxic than chemotherapy, does not cause fatigue, anemia, nausea, vomiting or the mobility problems faced by those suffering from this cancer .
"Given that people with castration-resistant metastatic prostate cancer have few options, we are very pleased with the results of this rigorous study," he explains. Johann S. de Bono, of the Cancer Research Institute in London, the Royal Marsden NHS Foundation Trust, and study coordinator .
In Mexico, this new drug has been presented by the pharmaceutical company Janssen, who assure that the abiraterone acetate (Zytiga) stops the production of androgens (promote the development of tumors) and their metastasis, which improves the quality of life of patients receiving treatment for prostate cancer.